Release Date: February 7, 2025
Expiration Date: February 7, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in pancreatic ductal adenocarcinoma (PDAC). In this educational program, these experts discuss current information on systemic therapy for metastatic PDAC based on the results from molecular tests. In particular, the expert faculty emphasizes recent changes and best practices for managing disease with uncommon driver aberrations.
This educational activity is an archive of the live symposium held on January 23, 2025.
Target Audience
This educational program is directed toward medical oncologists, pathologists, surgical oncologists, and other physicians involved in the management of pancreatic cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate the role of NRG1 and other genetic alterations in diagnosis and management
- Discuss current guidelines and treatment recommendations for the management of patients with advanced pancreatic cancer
- Analyze clinical trial data to inform the selection of emerging therapeutic agents for advanced pancreatic cancer
- Apply strategies to optimizing molecular testing algorithms using diverse testing modalities in advanced pancreatic cancer
E. Gabriela Chiorean, MD, FASCO
Professor of Medicine
Director, Clinical Research GI Oncology Program
University of Washington
Director, Clinical Research GI Oncology Program
Fred Hutchinson Cancer Center
Seattle Cancer Care Alliance
Seattle, WA
Disclosures: Advisor: Aadi, BPGBio, Bristol Myers Squibb, Merus, Pfizer, Purple, Regeneron, Takeda. Researcher: Affini-T, BioAtla, Biosplice, Bristol Myers Squibb, Erasca, Genentech, Gilead, Novartis.
Daniel H. Ahn, DO, MS
Professor
Division of Hematology/Medical Oncology
Lead, GI Oncology Translational Research Disease Working Group
Consultant
Mayo Clinic
Phoenix, AZ
Disclosures: Advisor: Bayer. Consultant: Incyte. Stockholder: Eli Lily, Natera.
Benjamin A. Weinberg, MD, FACP
Associate Professor of Medicine
Ruesch Center for the Cure of Gastrointestinal Cancers
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC
Disclosures: Consultant: Agenus, AstraZeneca, Daiichi Sankyo, DoMore Diagnostics, Foundation Medicine, Merus NV, Regeneron. Honoraria: Pimum. Speaker: AstraZeneca, Daiichi Sankyo, Jazz, Merus NV, Natera, Seagen, Sirtex, Taiho.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
